Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01810458 · ClinicalTrials.gov registry record
Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
A clinical trial, sponsored by University of Florida.
- Completed
- Registry status
- 109
- Enrollment target
NCT01810458: Completed study, sponsored by University of Florida.
NCT01810458 is a clinical trial that has completed, run by University of Florida. The registered enrollment target is 109 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01810458 has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 109 participants
- Enrollment target
Study Summary
We hypothesize that individuals with Alpha-1 Antitrypsin (AAT) deficiency have ongoing liver injury which is not detected by the usual blood tests used to look at liver function. This ongoing liver injury leads to cirrhosis in a significant number of adults with AAT deficiency.
Primary Outcome
An abdominal ultrasound will be done at the screening visit. A liver biopsy will be done on subjects who pass the screening process. The biopsy will be done within 30 days of the screening visit.
Interventions
- PROCEDURE Blood draw
- DEVICE Abdominal ultrasound
- PROCEDURE History and physical
- PROCEDURE Intravenous catheter
- OTHER Liver questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2013-10 |
| Est. Completion | 2019-09 |
What the finished NCT01810458 record still lists
NCT01810458 is an observational study that tracks outcomes without assigning an intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 5 interventions - of which Blood draw is the first listed.
NCT01810458 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01810458 about?
NCT01810458 is a clinical study titled "Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)". We hypothesize that individuals with Alpha-1 Antitrypsin (AAT) deficiency have ongoing liver injury which is not detected by the usual blood tests used to look at liver function. This ongoing liver injury leads to cirrhosis in a significant number of adults with AAT deficiency.
What is the current status of trial NCT01810458?
This trial is currently completed. The enrollment target is 109 participants. The study started on 2013-10. Estimated completion is 2019-09.
What interventions are being tested in trial NCT01810458?
The interventions under investigation include: Blood draw (PROCEDURE), Abdominal ultrasound (DEVICE), History and physical (PROCEDURE), Intravenous catheter (PROCEDURE), Liver questionnaire (OTHER).
Who is sponsoring clinical trial NCT01810458?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia